周一，Cassava Sciences经历了市场情绪的重大转变，Rodman & Renshaw将该公司股票评级从买入下调至卖出，目标价从之前的107.00美元大幅调整至2.00美元。此次降级紧随Cassava宣布其针对阿尔茨海默病潜在治疗药物simufilam的3期ReThink-ALZ研究未能达到关键终点。

在公告发布后，Cassava Sciences的股价在周一暴跌了85%。针对研究结果，Rodman & Renshaw分析师Elemer Piros将Cassava Sciences的评级从买入下调至卖出，并将目标价从之前的$107.00下调至$2.00。

智通财经APP获悉，周一，Cassava Sciences (SAVA.US)股价暴跌，截至发稿，该股跌超84%，报4.06美元。该公司表示，其simufilam治疗轻度至中度阿尔茨海默症的3期ReThink-ALZ研究的初步结果没有达到预先设定的共同主要终点、次要终点和探索性生物标志物终点。

(Reuters) -Cassava Sciences said it will stop all trials of its Alzheimer's disease drug after it failed a late-stage study, ...

Cassava Sciences Inc. (NASDAQ:SAVA) stock plunged Monday after the company released topline data from the Phase 3 ReThink-ALZ ...

Cassava Sciences stock plummeted Monday after the company's Alzheimer's treatment failed in Phase 3 testing. Billionaire Ken ...

Cassava Sciences shares are plunging in premarket trading and are losing most of their value after the biotech firm said its ...

(Reuters) -Cassava Sciences on Monday said its experimental Alzheimer's disease drug did not meet the main or secondary goals ...

AUSTIN, Texas, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA), a clinical-stage biotechnology ...

Cassava Sciences, a US biotech developing a novel, investigational treatment for Alzheimer’s disease (AD) dementia, was ...

Cassava Sciences’ stock plummets 85% after its Alzheimer’s treatment trial fails. Investigations and regulatory scrutiny add ...

Cassava Sciences’ phase 3 Alzheimer’s disease trial has missed its co-primary endpoints. With the study also missing ...